Search

Displaying results 1701 - 1710 of 10000 in total
  1. Drug

    Sonidegib

    go.drugbank.com/drugs/DB09143
    ApprovedInvestigational

    Sonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma.

    Synonyms: N-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridin-3-yl]-2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxamideCategories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index
  2. Drug

    Turpentine

    go.drugbank.com/drugs/DB11120
    Approved

    It is used as a solvent and base material in organic synthesis reactions. … Turpentine, also known as spirit of turpentine, oil of turpentine, and wood turpentine, is a liquid extracted from live trees, mainly pine, through distillation of resin.

    Categories: Compounds used in a research, industrial, or household settingProducts: Die Da Wan Hua Pain Relieving
  3. Drug

    Adapalene

    go.drugbank.com/drugs/DB00210
    ApprovedInvestigational

    On December 8th, 2008, Galderma Labs gained FDA approval for Epiduo®, a 0.1% adapalene, 2.5% BPO combination gel.[L12873] … [A193518] Differin®, produced by Galderma Labs, was first granted FDA approval on May 31st, 1996, as a 0.1% adapalene topical solution.

    Categories: Retinoids for Topical Use in Acne
  4. Drug

    Naxitamab

    go.drugbank.com/drugs/DB15965
    ApprovedInvestigational

    [L24454,A224604] Normally expressed during fetal development and in mature neurons, pain fibers, and skin cells, GD2 constitutes a highly efficient target in the treatment of neuroblastoma - it is widely … Naxitamab (humanized 3F8, hu3F8) is an IgG1 monoclonal antibody directed against the oncofetal differentiation antigen GD2 disialoganglioside.

  5. Drug

    Tick-borne encephalitis vaccine (whole virus, inactivated)

    go.drugbank.com/drugs/DB16611
    ApprovedInvestigational

    [A237505] TBE often manifests in a biphasic manner, with patients experiencing a flu-like illness followed by a variable asymptomatic period and then a second phase characterized by various neurological … [A237520, A237525] A second very similar vaccine, Encepur, followed in 1991.[A237520] Both vaccines are based on formaldehyde-inactivated whole virus.

    Products: FSME-Immun 0,25 ml Junior Injektionssuspension in einer Fertigspritze, FSME-Immun 0,5 ml Erwachsene Injektionssuspension in einer Fertigspritze
  6. Drug

    Risperidone

    go.drugbank.com/drugs/DB00734
    ApprovedInvestigational

    Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. … [L12885] Schizophrenia and various mood disorders are thought to be caused by an excess of dopaminergic D2 and serotonergic 5-HT2A activity, resulting in overactivity of central mesolimbic pathways

    Products: RISPERIDON AL 1MG, RISPERIDON AL 2MG
  7. Drug

    Asciminib

    go.drugbank.com/drugs/DB12597
    ApprovedInvestigational

    More specifically, it is an inhibitor of the ABL1 kinase activity of the BCR-ABL1 fusion protein[L38995] which serves as a driver of CML proliferation in most patients with the disease. … Asciminib is a tyrosine kinase inhibitor (TKI) used in the treatment of chronic-phase Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML).

  8. Drug

    Delandistrogene moxeparvovec

    go.drugbank.com/drugs/DB16802
    ApprovedInvestigational

    [L47026] DMD is an X-linked genetic disorder characterized by mutations in the dystrophin gene, leading to a deficiency in functional dystrophin protein. … of a muscle-specific promoter (MHCK7) to enhance expression in cardiac and skeletal muscles.

  9. Drug

    Inebilizumab

    go.drugbank.com/drugs/DB12530
    ApprovedInvestigational

    [A214283, A214286] Inebilizumab is a humanized afucosylated monoclonal IgG1 antibody directed against the broadly expressed B-cell surface antigen CD19. … [L52705] In December 2025, the FDA approved an additional indication for generalized myasthenia gravis. [L54838]

  10. Drug

    Eflornithine

    go.drugbank.com/drugs/DB06243
    ApprovedInvestigationalWithdrawn

    a 68% reduction in the risk of death were observed. … This approval is based on positive results obtained from a multi-site, single-arm, externally controlled study of children with high-risk neuroblastoma, where a 52% reduction in the risk of relapse and